Vistagen Therapeutics Class Action Lawsuit
Analysis based on 17 articles · First reported Jan 17, 2026 · Last updated Jan 29, 2026
The class action lawsuit against AnBogen Therapeutics could lead to a significant financial impact on the company if found liable, potentially affecting its stock price and investor confidence. For investors who purchased AnBogen Therapeutics stock during the Class Period, there is a potential for compensation through the lawsuit.
Rosen Law Firm has announced a class action lawsuit against AnBogen Therapeutics, alleging that the company made false and misleading statements regarding its fasedienol drug, an investigational pherine candidate for social anxiety disorder. The lawsuit claims that AnBogen Therapeutics provided overwhelmingly positive statements about the drug's future trial success, based on prior positive results and operational changes, while concealing material adverse facts concerning its Phase 3 PALISADE-3 trial. This allegedly caused investors to purchase AnBogen Therapeutics common stock at artificially inflated prices, leading to damages when the true details became known. The class period for the lawsuit is between April 1, 2024, and December 16, 2025, with a lead plaintiff deadline of March 16, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard